Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism

Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism

Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of cholesterol homeostasis, is associated with glucose metabolism. Liraglutide, a glucagon-like peptide-1 receptor agonist, can increase insulin secretion in a glucose-dependent manner and lower blood glucos...

Full description

Bibliographic Details
Main Authors: Sheng-Hua Yang, Rui-Xia Xu, Chuan-Jue Cui, Yin Wang, Ying Du, Zhi-Guo Chen, Yu-Hong Yao, Chun-Yan Ma, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Jing Sun, Bu-Xing Chen, Jian-Jun Li
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Cardiovascular Diabetology
Subjects:
PCSK9
Low-density lipoprotein receptor
Glucagon-like peptide-1
Liraglutide
Type 2 diabetes mellitus
Online Access:http://link.springer.com/article/10.1186/s12933-018-0689-9

Internet

http://link.springer.com/article/10.1186/s12933-018-0689-9

Similar Items